An S1 subunit vaccine and combination adjuvant (COVAC-1) elicits robust protection against SARS-CoV-2 challenge in African green monkeys

Lauren Garnett; Kaylie Tran; Mable Chan; Kevin Tierney; Zachary Schiffman; Jonathan Audet; Jocelyne Lew; Courtney Meilleur; Michael Chan; Kathy Manguiat; Nikesh Tailor; Robert Vendramelli; Yvon Deschambault; Guillaume Beaudoin-Bussières; Jonathan Richard; Andrés Finzi; Rick Higgins; Sylvia van den Hurk; Volker Gerdts; James Strong; Darryl Falzarano.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-496375

Documentos relacionados

  1. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
  2. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
  3. SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.
  4. Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination.
  5. Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
  6. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
  7. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
  8. Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.
  9. Natural Killer Cell Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity Against Plasmodium falciparum-Infected Red Blood Cells.
  10. Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters.